Research & Consultant Companies

Austria is spearheading an innovative approach to healthcare with the development of a programme theory for social prescribing (SP) in primary care environments. Implemented...

The collaborative digital landscape in European regulatory affairs sees a pivotal moment as the European Medicines Agency (EMA) and the Heads of Medicines Agencies...

As digital technologies evolve, healthcare regulators face increasing demands to integrate real-world data into regulatory decision-making processes. This is a critical undertaking as it...

Leaders from across medical regulatory bodies are steering transformative dialogue and decisions within the HMA-EMA joint Network Data Steering Group. With emerging topics such...

Digital health technologies are stepping into the spotlight, offering new pathways for parents to tackle perinatal mental health risks. With up to 20% of...

A glaring gap in Finland's healthcare system has been spotlighted. Finland lags behind its Nordic counterparts by not screening newborns for Spinal Muscular Atrophy...

Leber's hereditary optic neuropathy (LHON), a condition that leads to the gradual loss of vision, primarily affects adolescents and adults who have mitochondrial mutations....

Multiple myeloma, a complex cancer affecting plasma cells in the bone marrow, continues to challenge medical researchers as they seek effective treatments. Despite existing...

Amid significant developments, the European Union has withdrawn the orphan medicinal product designation for a treatment aimed at diffuse large B-cell lymphoma (DLBCL), effective...

In the ambitious pursuit of addressing rare diseases, Pharma Gateway AB has focused its efforts on developing a breakthrough treatment approach for peripheral T-cell...

Friedreich’s ataxia stands as a daunting challenge in the medical landscape due to its devastating progression and life-threatening nature. Characterized by symptoms like movement...

Zeteletinib, a prospective therapeutic agent targeting medullary thyroid carcinoma, finds itself amid regulatory transition within the European Union. Initially granted orphan designation in February...

A groundbreaking advancement in leukemia therapy emerged as the European Union designated a new treatment approach as "orphan" for tackling acute lymphoblastic leukaemia (ALL),...

The European Medicines Agency's recent decision to retract the orphan designation for a promising treatment targeting diffuse large B-cell lymphoma underscores the inherent challenges...

The quest for effective treatments in the realm of rare diseases often poses significant challenges, but advancements continue to unfold in Europe. One notable...